GENMAB files Annual Report with US Securities and Exchange Commission

Media emissions

Copenhagen, Denmark; February 12, 2025

GENMAB submitted Form 20-F for the financial year 2024 to US SEC

Genmab A/S. (Nasdaq: GMAB) announced today that it has submitted its annual report for the financial year 2024 on Form 20-F with US Securities and Exchange Commission (SEC), with reference parts in Genmab A/S annual report 2024. Both reports are available through Sec’s website, www.sec.gov and Genmab’s website, www.genmab.com.

About Genmab
Genmab is an international biotechnology company with a core purpose to guide its unstoppable team to strive to improve the lives of patients with innovative and differentiated antibody therapy. For more than 25 years, the passionate, innovative and cooperative team has invented the next generation of antibody technology platforms and utilized translational, quantitative and computer sciences, which resulted in a proprietary pipeline including bisch-specific T-cell-enforcement, antibody control, the next generation immigrant, the next generation immigration, the next generation immigrant, the next generation immigrant, the next generation, the next generation, the next generation, the next generation, the next generation, the next generation, the next generation, In 2030, Genmab’s vision is to change the lives of people with cancer and other serious illnesses with knock-your socks-off (kyso) antibody medication^®.?

Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark, with international presence in North America, Europe and Asia and the Pacific. For more information, visit Genmab.com? And follow us on LinkedIn and X.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: [email protected]

Andrew Carlsen, Deputy President, Head of Invester’s Relationships
T: +45 3377 9558; E: [email protected]

This media edition contains prominent statements. The words “faith”, “expect”, “predict”, “intention” and “plan” and similar expressions identify inducing statements. Actual results or performance may differ significantly from future results or performance expressed or implied by such statements. Important factors that may lead to our actual results or performance differing significantly, among other things, risks associated with preclinical and clinical development of products, uncertainties related to the result and the construction of clinical trials including unforeseen security issues, uncertainties related to product manufacturing, the lack on market acceptance of our products, our inability to manage growth, the competition environment in relation to our business area and markets, our inability to attract and retain suitable qualified personnel, incredibility or lack of protection of our patents and ownership, our relationships with connected units, changes And development in technology that can make our products or technology outdated and other factors. For a further discussion about these risks, see sections on risk management in Genmab’s latest financial reports available on www.genmab.com
and the risk factors included in Genmab’s latest annual report on Form 20-F and other applications with US Securities and Exchange Commission (SEC), which are available on www.sec.gov. Genmab does not undertake any obligation to update or revise forward -looking statements in this media issuance or to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless it is required by law.

Genmab A/S and/or its subsidiaries own the following brands: Genmab^®; The Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped GenMAB logo^®; Humax^®; Duobody^®; Hexabody^®; Duohexabody^®Hexelect^®
And Kyso^®.